Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae. by Nakamura Shigeki et al.
1 
 
Melting curve analysis for rapid detection of topoisomerase gene mutations in 
Haemophilus influenzae 
Running title: Melting curve assay of quinolone-resistant H. influenzae  
 
Shigeki Nakamura1), *Katsunori Yanagihara1) 2), Yoshitomo Morinaga1) 2), Koichi 
Izumikawa1), Masafumi Seki1), Hiroshi Kakeya1), Yoshihiro Yamamoto1), Shimeru 
Kamihira2) and Shigeru Kohno1) 3) 
 
1)Second Department of Internal Medicine, 2)Department of Laboratory Medicine, and 
3)Division of Molecular & Clinical Microbiology, Department of Molecular 
Microbiology & Immunology, Nagasaki University Graduate School of Medical 
Science, Nagasaki, Japan 
 
*Corresponding author: Katsunori Yanagihara 
Department of Laboratory Medicine, Nagasaki University School of Medicine 
1–7–1 Sakamoto, Nagasaki 852-8501, Japan 
Tel: +81 – 95 – 819 – 7276; Fax: +81 – 95 – 849 – 7285 
E-mail: k-yanagi@nagasaki-u.ac.jp 
2 
 
Abstract 
We combined a real time PCR assay with melting curve analysis to rapidly genotyping 
quinolone resistance-determining regions (QRDRs) of gyrase A and topoisomerase IV 
genes in Haemophilus influenzae. This assay is a useful tool for the detection of 
fluoroquinolone resistance and the early detection of preexisting QRDR mutations.  
H. influenzae is a major causative pathogen isolated from infections including acute 
and chronic respiratory infections, acute otitis media, sinusitis, and meningitis in 
pediatric patients. Recent reports have noted the prevalence of fluoroquinolone 
(FQ)-resistant H. influenzae (1, 3, 4, 9, 11, 14, 20, 22, 26). FQ-resistant H. influenzae 
often carries mutations in the quinolone resistance–determining regions (QRDRs) of the 
gyrA and the parC, which encode subunits of DNA gyrase and topoisomerase IV, 
respectively (9, 11, 16, 18, 23). Real-time PCR methods combined with melting curve 
analysis (PCR-MCA) are a useful tool for the rapid detection of key gene mutations 
associated with drug resistance in various microorganisms (13, 24, 25), but there are no 
reports about H. influenzae. The aim of this study was to develop a PCR-MCA method 
for H. influenzae strains, targeting a total of four QRDR positions in the gyrA (codons 
84 and 88) and the parC (codons 84 and 88) that are frequently associated with FQ 
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resistance (9, 11, 16, 23). This current method could identify simultaneously both the 
gyrA and the parC mutations by only one PCR performance. 
Seventeen H. influenzae clinical isolates were used. Ten of the strains were susceptible 
to FQ, and seven of the strains had low susceptibility or were resistant to FQ. The seven 
FQ resistant/low susceptibility strains were: 1 strain (NUH-1) from Nagasaki University 
Hospital, 1 strain (BY-1) from Bayer (Osaka, Japan), 2 strains (DR-1, DS-2) from 
Daiichi-Sankyo (Tokyo, Japan), and 3 strains (MSC24060, MSC27995, MSC11438) 
kindly provided by Meiji-Seika Kaisha (Tokyo, Japan) (21). The 10 FQ-susceptible 
strains were isolated at Nagasaki University Hospital. Identification of H. influenzae 
was confirmed by colony morphology, Gram staining, growth on chocolate agar, and 
the X and V factor requirement. The minimum inhibitory concentrations (MICs) of 
ciprofloxacin (CPFX), sparfloxacin (SPFX), levofloxacin (LVFX), gatifloxacin (GTFX), 
moxifloxacin (MXFX), garenoxacin (GRNX), and sitafloxacin (STFX) were 
determined by a broth dilution method using Haemophilus test medium according to the 
recommendations of the Clinical and Laboratory Standards Institute (CLSI) (5). H. 
influenzae ATCC51907 was used for quality control. 
4 
 
DNA was extracted from each strain by using a QIAamp DNA mini kit (QIAGEN, 
Hilden, Germany). Sequences of the oligonucleotides and probes are shown in Tables 
1A and 1B. The sequences are from the known sequences of the parC and gyrA genes, 
which were derived from GenBank accession no. NP439678 and NP439419, 
respectively. To identify mutations in the QRDRs of gyrA and parC in these strains, we 
performed PCR and direct DNA sequencing according to the method of Vila et al. (26). 
Real-time PCR methods combined with melting curve analysis (MCA-PCR) was 
performed in a total volume of 10 μl containing 2 μl of DNA template, 5 μl of 
LightCycler 480 Probe Master mixture (Roche Diagnostics, Basel, Switzerland), a 0.2 
μM concentration of each probe, and a 0.5 μM concentration of each primer. Thermal 
cycling was performed with an initial hold for 5 min at 95°C, followed by 30 cycles of 
10 s at 95°C, 10 s at 58°C, and 12 s at 72°C. A melting curve was generated by cooling 
the reaction mixture to 35°C for 10 s, followed by heating to 90°C at a rate of 0.2°C/s. 
The PCR-MCA assay was performed using LightCycler 480 Basic software (Roche 
Diagnostics, Basel, Switzerland). The total assay time was approximately 1 h. The 
QRDR DNA sequencing results were compared with the sequence of strain Rd 
(GenBank accession no. NC000907), which was used as the wild-type standard strain. 
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Using specific probes for the wild-type strain, all of the mutant strains showed 
characteristic melting peaks with a distinct Tm value, as shown in Figure 1. The 
minimum Tm shifts for mutant strains compared to the wild-type strain were 6.13°C for 
parC codons 84 and 88, 11.58°C for gyrA codon 84, and 7.9°C for gyrA codon 88. The 
PCR-MCA assay correctly detected seven LVFX low susceptibility/resistant strains, as 
determined by a comparison with sequencing results (Table 2). From sequencing results, 
all seven FQ low susceptibility/resistant strains had at least two single amino acid 
substitutions at four QRDR positions (Table 3). All LVFX-susceptible H. influenzae 
strains had the same Tm value as the wild-type strain, and sequencing results confirmed 
that these were in fact wild-type strains (data not shown).  
We compared the ability of the present PCR-MCA assay to detect FQ susceptibility in 
seventeen H. influenzae strains with that of the conventional phenotypic method. All 
LVFX-susceptible strains which had no mutation in condons 84 and 88 of gyrA and 
parC classified susceptible according to CLSI criteria (6) (data not shown). As shown in 
Table 3, the mutation profiles for the QRDRs in the gyrA and parC revealed a close 
relationship between the MIC level and the number of QRDR mutations. Previous 
studied have found that the conventional phenotypic method failed to detect strains that 
have a single QRDR mutation; these strains have the potential to develop into a highly 
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resistant pathogen (7). Several reports have noted that a significant number of 
Streptococcus pneumoniae isolates already have a single step mutation, and prone to 
acquiring second step mutation (19). Unfortunately, our study lacks a collection of 
single-mutant strains. It was reported that the selection window for ciprofloxacin with 
wild-type cells was below serum drug concentrations in human volunteers administered 
twice-daily of 500mg (10). But Odoul et al. reported the median area under the 
inhibitory curve was decreased about half the proposed target value for ciprofloxacin in 
the cystic fibrosis patient receiving 15 mg/kg twice a day regimen of oral ciprofloxacin 
(15). Furthermore Pérez-Vázquez et al. reported that hypermutability is a risk condition 
for the development of fluoroquinolone-resistant H. influenzae (17) and Li et al. also 
reported the stepwise selection of ciprofloxacin-resistant H. influenzae mutants and 
could be the high level resistant strain (12). Increasing the time that drug concentration 
fall into the mutant selection window causes the mutation (8). Actually, the previously 
reported strains that failed treatment had a double mutant in the gyrA and the parC (2). 
We emphasize the clinical importance of the detection of first-step QRDR mutations in 
either gyrA or parC for attempting to predict evolution into FQ resistance. In addition, 
we should consider the FQ dosage carefully to avoid the low FQ concentration when we 
treat the patients who have chronic lung disease. 
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In conclusion, the PCR-MCA assay was easily and quickly performed and had an 
accuracy that was at least as satisfactory as that of the conventional phenotypic method. 
FQ-resistant H. influenzae is expected to become a more important pathogen in the 
future, because FQ is the most effective antibiotic against H. influenzae, and the number 
of FQ-resistant strain may arise further along with the recent increase of FQ prescription. 
Although additional studies are need, we anticipate that this PCR-MCA assay may be a 
useful tool for surveillance studies in the screening of FQ resistance as an alternative to 
DNA nucleotide sequencing because this PCR-MCA assay can recognize the gyrA and 
the parC mutants more clearly, easily and rapidly than sequencing. 
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Figure legend 
Figure 1. Melting peak patterns for QRDR mutants with substitutions in parC and gyrA. Melting 
curve analysis was performed with the 175-bp amplicon of the parC gene and the 197-bp amplicon 
of the gyrA gene. Panels A, B and C show melting peak patterns for codons 84 and 88 of the parC 
gene, codon 84 of the gyrA gene and codon 88 of the gyrA gene, respectively. Each value on the y 
axis reveals the ratio of the first negative derivative of the change in fluorescence (dF) to the 
variation in temperature. 
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